Registries’ Role in Medicare Coverage of New Drugs for Alzheimer’s Disease
In a Viewpoint article, authors consider how a CMS registry could be used in evaluating “whether monoclonal antibodies are reasonable and necessary in the Medicare
In a Viewpoint article, authors consider how a CMS registry could be used in evaluating “whether monoclonal antibodies are reasonable and necessary in the Medicare
“As a nation, we still have a long way to go to provide quality health care to the most vulnerable Americans,” authors write in a
In a Medicare theme issue of Health Affairs, authors describe the growth in enrollment in Medicare Advantage (MA) and how favorable selection has resulted in
“The Medicare trust fund cannot become a blank check for any drug or device manufacturer granted authorization by the FDA,” write authors of a Viewpoint
A study of evidence-based medicines for 6 cardiovascular diseases (CVDs; atrial fibrillation, heart failure, hyperlipidemia, hypertension, post–acute coronary syndrome secondary prevention, and stable angina) shows
Utilization management for Medicare Part D oral oncology drugs increased between 2010 and 2020, according to a study of formulary files. “Prior authorization was the
Products approved on an accelerated basis by FDA in 2009 through 2019 accounted for an inordinate amount of commerical health plan and enrollee out-of-pocket spending
From 2017 to 2020, inflationary rebates offset 2% to 12% of Medicaid medication spending, researchers report: “State Medicaid programs cover nearly all Food and Drug
A Vaccines for Adults (VFA) program should be created to close the vaccine-coverage gap currently existing among Americans without health insurance, CDC officials write in
Newly approved prescription drugs with orphan drug designations were as lucrative over the first 5 years as agents approved for more common conditions, according to